Skip to main content
Top
Published in: Journal of Translational Medicine 1/2012

Open Access 01-12-2012 | Methodology

Protein L: a novel reagent for the detection of Chimeric Antigen Receptor (CAR) expression by flow cytometry

Authors: Zhili Zheng, Nachimuthu Chinnasamy, Richard A Morgan

Published in: Journal of Translational Medicine | Issue 1/2012

Login to get access

Abstract

Background

There has been significant progress in the last two decades on the design of chimeric antigen receptors (CAR) for adoptive immunotherapy targeting tumor-associated antigens. Structurally CARs consist of a single chain antibody fragment directed against a tumor-associated antigen fused to an extracellular spacer and transmembrane domain followed by T cell cytoplasmic signaling moieties. Currently several clinical trials are underway using gene modified peripheral blood lymphocytes (PBL) with CARs directed against a variety of tumor associated antigens. Despite the improvements in the design of CARs and expansion of the number of target antigens, there is no universal flow cytometric method available to detect the expression of CARs on the surface of transduced lymphocytes.

Methods

Currently anti-fragment antigen binding (Fab) conjugates are most widely used to determine the expression of CARs on gene-modified lymphocytes by flow cytometry. The limitations of these reagents are that many of them are not commercially available, generally they are polyclonal antibodies and often the results are inconsistent. In an effort to develop a simple universal flow cytometric method to detect the expression of CARs, we employed protein L to determine the expression of CARs on transduced lymphocytes. Protein L is an immunoglobulin (Ig)-binding protein that binds to the variable light chains (kappa chain) of Ig without interfering with antigen binding site. Protein L binds to most classes of Ig and also binds to single-chain antibody fragments (scFv) and Fab fragments.

Results

We used CARs derived from both human and murine antibodies to validate this novel protein L based flow cytometric method and the results correlated well with other established methods. Activated human PBLs were transduced with retroviral vectors expressing two human antibody based CARs (anti-EGFRvIII, and anti-VEGFR2), two murine antibody derived CARs (anti-CSPG4, and anti-CD19), and two humanized mouse antibody based CARs (anti-ERBB2, and anti-PSCA). Transduced cells were stained first with biotin labeled protein L followed by phycoerythrin (PE)-conjugated streptavidin (SA) and analyzed by flow cytometry. For comparison, cells were stained in parallel with biotin conjugated goat-anti-mouse Fab or CAR specific fusion proteins. Using protein L, all CAR transduced lymphocytes exhibited specific staining pattern ranging from 40 to 80% of positive cells (compared to untransduced cells) and staining was comparable to the pattern observed with anti-Fab antibodies.

Conclusion

Our data demonstrate the feasibility of employing Protein L as a general reagent for the detection of CAR expression on transduced lymphocytes by flow cytometry.
Appendix
Available only for authorised users
Literature
1.
go back to reference Cooper LJ: Off-the-shelf T-cell therapy. Blood. 2010, 116: 4741-4743. 10.1182/blood-2010-10-308379.CrossRefPubMed Cooper LJ: Off-the-shelf T-cell therapy. Blood. 2010, 116: 4741-4743. 10.1182/blood-2010-10-308379.CrossRefPubMed
2.
go back to reference Gross G, Waks T, Eshhar Z: Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc Natl Acad Sci USA. 1989, 86: 10024-10028. 10.1073/pnas.86.24.10024.CrossRefPubMedPubMedCentral Gross G, Waks T, Eshhar Z: Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc Natl Acad Sci USA. 1989, 86: 10024-10028. 10.1073/pnas.86.24.10024.CrossRefPubMedPubMedCentral
3.
go back to reference Dotti G, Savoldo B, Brenner M: Fifteen years of gene therapy based on chimeric antigen receptors: "are we nearly there yet?". Hum Gene Ther. 2009, 20: 1229-1239. 10.1089/hum.2009.142.CrossRefPubMedPubMedCentral Dotti G, Savoldo B, Brenner M: Fifteen years of gene therapy based on chimeric antigen receptors: "are we nearly there yet?". Hum Gene Ther. 2009, 20: 1229-1239. 10.1089/hum.2009.142.CrossRefPubMedPubMedCentral
4.
go back to reference Jena B, Dotti G, Cooper LJ: Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor. Blood. 2010, 116: 1035-1044. 10.1182/blood-2010-01-043737.CrossRefPubMedPubMedCentral Jena B, Dotti G, Cooper LJ: Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor. Blood. 2010, 116: 1035-1044. 10.1182/blood-2010-01-043737.CrossRefPubMedPubMedCentral
5.
go back to reference Zhao Y, Wang QJ, Yang S, Kochenderfer JN, Zheng Z, Zhong X, Sadelain M, Eshhar Z, Rosenberg SA, Morgan RA: A herceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activity. J Immunol. 2009, 183: 5563-5574. 10.4049/jimmunol.0900447.CrossRefPubMed Zhao Y, Wang QJ, Yang S, Kochenderfer JN, Zheng Z, Zhong X, Sadelain M, Eshhar Z, Rosenberg SA, Morgan RA: A herceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activity. J Immunol. 2009, 183: 5563-5574. 10.4049/jimmunol.0900447.CrossRefPubMed
6.
go back to reference Chinnasamy D, Yu Z, Theoret MR, Zhao Y, Shrimali RK, Morgan RA, Feldman SA, Restifo NP, Rosenberg SA: Gene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in mice. J Clin Invest. 2010, 120: 3953-3968. 10.1172/JCI43490.CrossRefPubMedPubMedCentral Chinnasamy D, Yu Z, Theoret MR, Zhao Y, Shrimali RK, Morgan RA, Feldman SA, Restifo NP, Rosenberg SA: Gene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in mice. J Clin Invest. 2010, 120: 3953-3968. 10.1172/JCI43490.CrossRefPubMedPubMedCentral
7.
go back to reference Burns WR, Zhao Y, Frankel TL, Hinrichs CS, Zheng Z, Xu H, Feldman SA, Ferrone S, Rosenberg SA, Morgan RA: A high molecular weight melanoma-associated antigen-specific chimeric antigen receptor redirects lymphocytes to target human melanomas. Cancer Res. 2010, 70: 3027-3033. 10.1158/0008-5472.CAN-09-2824.CrossRefPubMedPubMedCentral Burns WR, Zhao Y, Frankel TL, Hinrichs CS, Zheng Z, Xu H, Feldman SA, Ferrone S, Rosenberg SA, Morgan RA: A high molecular weight melanoma-associated antigen-specific chimeric antigen receptor redirects lymphocytes to target human melanomas. Cancer Res. 2010, 70: 3027-3033. 10.1158/0008-5472.CAN-09-2824.CrossRefPubMedPubMedCentral
8.
go back to reference Kochenderfer JN, Feldman SA, Zhao Y, Xu H, Black MA, Morgan RA, Wilson WH, Rosenberg SA: Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor. J Immunother. 2009, 32: 689-702. 10.1097/CJI.0b013e3181ac6138.CrossRefPubMedPubMedCentral Kochenderfer JN, Feldman SA, Zhao Y, Xu H, Black MA, Morgan RA, Wilson WH, Rosenberg SA: Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor. J Immunother. 2009, 32: 689-702. 10.1097/CJI.0b013e3181ac6138.CrossRefPubMedPubMedCentral
9.
go back to reference Nilson BH, Solomon A, Bjorck L, Akerstrom B: Protein L from Peptostreptococcus magnus binds to the kappa light chain variable domain. J Biol Chem. 1992, 267: 2234-2239.PubMed Nilson BH, Solomon A, Bjorck L, Akerstrom B: Protein L from Peptostreptococcus magnus binds to the kappa light chain variable domain. J Biol Chem. 1992, 267: 2234-2239.PubMed
10.
go back to reference Bjorck L: Protein L. a novel bacterial cell wall protein with affinity for Ig L chains. J Immunol. 1988, 140: 1194-1197.PubMed Bjorck L: Protein L. a novel bacterial cell wall protein with affinity for Ig L chains. J Immunol. 1988, 140: 1194-1197.PubMed
11.
go back to reference Nilson BH, Logdberg L, Kastern W, Bjorck L, Akerstrom B: Purification of antibodies using protein L-binding framework structures in the light chain variable domain. J Immunol Methods. 1993, 164: 33-40. 10.1016/0022-1759(93)90273-A.CrossRefPubMed Nilson BH, Logdberg L, Kastern W, Bjorck L, Akerstrom B: Purification of antibodies using protein L-binding framework structures in the light chain variable domain. J Immunol Methods. 1993, 164: 33-40. 10.1016/0022-1759(93)90273-A.CrossRefPubMed
Metadata
Title
Protein L: a novel reagent for the detection of Chimeric Antigen Receptor (CAR) expression by flow cytometry
Authors
Zhili Zheng
Nachimuthu Chinnasamy
Richard A Morgan
Publication date
01-12-2012
Publisher
BioMed Central
Published in
Journal of Translational Medicine / Issue 1/2012
Electronic ISSN: 1479-5876
DOI
https://doi.org/10.1186/1479-5876-10-29

Other articles of this Issue 1/2012

Journal of Translational Medicine 1/2012 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine